^
    Back
    Association details:
    Biomarker:ERCC2 E606Q
    Cancer:Urothelial Cancer
    Drug:cisplatin (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Front Oncol
    Title:

    Genomic Profiling Identified ERCC2 E606Q Mutation in Helicase Domain Respond to Platinum-Based Neoadjuvant Therapy in Urothelial Bladder Cancer

    Published date:
    08/26/2020
    Excerpt:
    The patient (Case #19) was diagnosed with MIBC...The tumor also harbored ERCC2 p.E606Q... The patient received neoadjuvant chemotherapy with cisplatin and gemcitabine (3 courses) before cystectomy. After chemotherapy, we observed tumor and lymph node were remarkably shrunk by CT examination.
    DOI:
    https://doi.org/10.3389/fonc.2020.01643